XLV catalysts
Catalysts and events linked to XLV, newest first.
XLV stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| UnitedHealth reiterates 13-16% growth as AI cuts prior authorizations by 30% 2026-10-18 · Up | healthcare index weight stabilization | UNH is the heaviest weighting in the XLV index benchmark. | Not recorded |
| UnitedHealth Reaffirms 13% to 16% Target as Q3 Prior Authorizations Fall 30% 2026-10-18 · Up | defensive margin stability supporting healthcare sector multiple | UNH represents the largest weighting in XLV, stabilizing health insurance sub-industry sentiment. | Not recorded |
| UnitedHealth reiterates 13% to 16% growth target on 30% prior auth drop 2026-10-18 · Up | healthcare sector benchmark support via top managed care weighting | UNH represents the largest single holding in U.S. managed care and health insurance ETF allocations. | Not recorded |
| Veeva Systems rises to $301.63 on projected 14.2% EPS and 15.1% revenue expansion 2026-10-14 · Watch | healthcare technology valuation read-through | Veeva is a key constituent in healthcare technology and enterprise life sciences platforms. | Not recorded |
| UnitedHealth posts 60% YoY EPS gain on medical cost control; J&J earnings decline 7.5% 2026-10-14 · Up | heavy index weighting of UNH and JNJ earnings guidance revisions | UNH and JNJ are top index constituents in the healthcare sector. | Not recorded |
| Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line Growth 2026-10-13 · Up | defensive large-cap healthcare multiple expansion from medtech earnings stability | Broad healthcare sector constituents exhibited positive relative strength during session decline. | Not recorded |
| DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS Expansion 2026-10-11 · Watch | healthcare provider operational margin normalization lifting defensive sector earnings | Provider subsector gains support broader healthcare equity multiples. | Not recorded |
| UnitedHealth Group Sets Up for Q3 Results with 41.1% Projected EPS Expansion 2026-10-10 · Up | large-cap healthcare index weight transmission | UNH is a top weighting across major US healthcare benchmark indices. | Not recorded |
Do these developments change your position?
Review XLV alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-18UnitedHealth reiterates 13% to 16% growth target on 30% prior auth dropUNH XLV+1.36%
- 2026-10-18UnitedHealth Reaffirms 13% to 16% Target as Q3 Prior Authorizations Fall 30%UNH XLV+1.36%
- 2026-10-18UnitedHealth Reaffirms 13% to 16% Target as Q3 Prior Authorizations Fall 30%UNH XLV+1.36%
- 2026-10-18UnitedHealth reiterates 13% to 16% growth target on 30% prior auth dropUNH XLV+1.36%
- 2026-10-18UnitedHealth reiterates 13-16% growth as AI cuts prior authorizations by 30%UNH XLV+1.36%
- 2026-10-14UnitedHealth posts 60% YoY EPS gain on medical cost control; J&J earnings decline 7.5% → Bullish XLVXLV+1.86%
- 2026-10-14UnitedHealth posts 60% YoY EPS gain on medical cost control; J&J earnings decline 7.5%XLV+1.86%
- 2026-10-14Veeva Systems rises to $301.63 on projected 14.2% EPS and 15.1% revenue expansionVEEV XLV+1.86%
- 2026-10-14UnitedHealth posts 60% YoY EPS gain on medical cost control; J&J earnings decline 7.5%JNJ UNH XLV+1.47%
- 2026-10-13Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line GrowthABT IHI XLV+2.53%
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA XLV+3.45%
- 2026-10-10UnitedHealth Group Sets Up for Q3 Results with 41.1% Projected EPS Expansion → Bullish XLV → Bullish XLVXLV+3.45%
- 2026-10-10UnitedHealth Group Sets Up for Q3 Results with 41.1% Projected EPS Expansion → Bullish XLVXLV+3.45%
- 2026-10-10UnitedHealth Group Sets Up for Q3 Results with 41.1% Projected EPS ExpansionXLV+3.45%
- 2026-10-10UnitedHealth Group Sets Up for Q3 Results with 41.1% Projected EPS ExpansionUNH XLV+4.64%
- 2026-10-10UnitedHealth Group Sets Up for Q3 Results with 41.1% Projected EPS ExpansionUNH XLV+4.64%
- 2026-10-09UnitedHealth Previews 41% Q3 EPS Growth Ahead of October 13 Reporting DateUNH XLV+4.64%
- 2026-10-09UnitedHealth Faces Revenue Contraction Ahead of Q3 Results on October 13UNH XLV+4.64%
- 2026-10-04UnitedHealth Prepares Oct 13 Q3 Print Following Q2 Medical Care Ratio of 86.7%UNH XLV+2.39%
- 2026-10-04UnitedHealth Faces Medical Care Ratio Scrutiny Ahead of Oct 13 Q3 EarningsUNH XLV+2.39%
- 2026-10-04UnitedHealth Prepares Q3 Earnings With Focus on Medical Care RatioUNH XLV+2.39%
- 2026-10-01Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 PrintMRK XLV+1.18%
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of MixBMY XLV+1.33%
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growthXLV+1.33%
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of MixBMY XLV+1.33%
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of MixBMY XLV+1.33%
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growthBMY XLV+1.33%
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 RevenueBMY XLV+1.33%
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverageXLV+1.37%
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverageXLV+1.37%
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverageLLY XLV+1.37%
- 2026-09-09WHO South-East Asia members adopt Dili Declaration on health workforce equity in specialized careBND XLV+0.71%
- 2026-08-06Eli Lilly rises 5% on surging obesity drug sales and Q2 beat → Bullish XLVXLV+2.39%
- 2026-08-06Eli Lilly shares rise 5% on surging Mounjaro and Zepbound sales → Bullish XLVXLV+2.39%
- 2026-08-06Eli Lilly rises 5% on surging obesity drug sales and Q2 beatLLY XLV+2.39%
- 2026-08-06Eli Lilly shares rise 5% on surging Mounjaro and Zepbound salesLLY XLV+2.39%
- 2026-08-06Eli Lilly rises 5% on surging obesity drug sales and Q2 beatLLY XLV+2.39%
- 2026-08-06Eli Lilly shares rise 5% on surging Mounjaro and Zepbound salesLLY XLV+2.39%
- 2026-08-03US CDC ends national hantavirus response program following reassessment of risksCI UNH XLV+1.11%
- 2026-06-02State Street's XLV healthcare ETF outperforms Invesco's RSPH.RSPH XLV+5.63%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.